Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media. The company also provides chromatography products comprising OPUS pre-packed chromatography columns, which are used in the purification of antibodies and recombinant proteins; and OPUS PD smaller-scale columns that are used in the high throughput process development screening, viral validation studies, and scale down validation of chromatography processes. Its chromatography products also comprise ELISA kits, which are analytical test kits to detect the presence of proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company provides filtration products, such as XCell ATF systems that are filtration devices used in upstream processes to remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest; Sius TFF line of cassettes used in downstream biologic drug purification and formulation processes; KrosFlo line of hollow-fiber cartridges and TFF systems; Spectra/Por portfolio of laboratory and process dialysis products; and Pro-Connex single-use hollow-fiber module-bag-tubing sets. Repligen Corporation sells its bioprocessing products to life sciences companies, biopharmaceutical companies, and contract manufacturing organizations. The company has a collaboration agreement with Navigo Proteins GmbH for the advancement of affinity ligands used in monoclonal antibody (mAb) and non-mAb downstream purification processes. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone781-250-0111
Debt
Current Ratio2.06
Quick Ratio1.73
Price-To-Earnings
Sales & Book Value
Annual Sales$141.24 million
Price / Sales17.15
Price / Cash Flow63.71
Price / Book4.07
Profitability
Net Income$28.35 million
Net Margins12.61%
Return on Assets4.31%
Miscellaneous
Employees476
OptionableOptionable
Repligen (NASDAQ:RGEN) Frequently Asked Questions
What is Repligen's stock symbol?
Repligen trades on the NASDAQ under the ticker symbol "RGEN."
How were Repligen's earnings last quarter?
Repligen Co. (NASDAQ:RGEN) posted its quarterly earnings data on Thursday, November, 1st. The biotechnology company reported $0.20 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.18 by $0.02. The biotechnology company earned $49.53 million during the quarter, compared to analyst estimates of $46.69 million. Repligen had a return on equity of 5.39% and a net margin of 12.61%. The business's quarterly revenue was up 35.4% on a year-over-year basis. During the same period last year, the company posted $0.15 EPS. View Repligen's Earnings History.
When is Repligen's next earnings date?
What guidance has Repligen issued on next quarter's earnings?
Repligen issued an update on its FY18 earnings guidance on Thursday, November, 1st. The company provided EPS guidance of $0.71-0.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.71. The company issued revenue guidance of $191-194 million, compared to the consensus revenue estimate of $187.95 million.
What price target have analysts set for RGEN?
7 analysts have issued 1 year target prices for Repligen's shares. Their forecasts range from $55.00 to $70.00. On average, they expect Repligen's stock price to reach $60.25 in the next year. This suggests a possible upside of 9.1% from the stock's current price. View Analyst Price Targets for Repligen.
What is the consensus analysts' recommendation for Repligen?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Repligen.
Has Repligen been receiving favorable news coverage?
Headlines about RGEN stock have trended somewhat positive this week, according to InfoTrie. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Repligen earned a news impact score of 1.9 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Who are some of Repligen's key competitors?
Some companies that are related to Repligen include Qiagen (QGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), BIO-TECHNE (TECH), Ablynx (ABLYF), Allogene Therapeutics (ALLO), argenx (ARGX), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE) and Regenxbio (RGNX).
Who are Repligen's key executives?
Repligen's management team includes the folowing people:
- Mr. Anthony J. Hunt, CEO, Pres, Director & Member of Scientific Advisory Board (Age 54)
- Mr. Jon K. Snodgres, CFO & Sec. (Age 52)
- Mr. Steve Curran, VP of Global Operations
- Ms. Sondra S. Newman, Sr. Director of Investor Relations
- Mr. Stephen Tingley, VP of Sales
Who are Repligen's major shareholders?
Repligen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Summit Creek Advisors LLC (0.20%), Louisiana State Employees Retirement System (0.03%), Fox Run Management L.L.C. (0.02%) and First Hawaiian Bank (0.00%). Company insiders that own Repligen stock include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel, Roy T Eddleman and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen.
Which major investors are selling Repligen stock?
RGEN stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC and Louisiana State Employees Retirement System. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel, Roy T Eddleman and Thomas F Ryan Jr. View Insider Buying and Selling for Repligen.
Which major investors are buying Repligen stock?
How do I buy shares of Repligen?
Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Repligen's stock price today?
One share of RGEN stock can currently be purchased for approximately $55.24.
How big of a company is Repligen?
Repligen has a market capitalization of $2.42 billion and generates $141.24 million in revenue each year. The biotechnology company earns $28.35 million in net income (profit) each year or $0.69 on an earnings per share basis. Repligen employs 476 workers across the globe.
What is Repligen's official website?
How can I contact Repligen?
Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected]
MarketBeat Community Rating for Repligen (NASDAQ RGEN)
MarketBeat's community ratings are surveys of what our community members think about Repligen and other stocks. Vote "Outperform" if you believe RGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
